Breaking News Instant updates and real-time market news.

AGLE

Aeglea BioTherapeutics

$7.02

0.08 (1.15%)

07:48
05/07/19
05/07
07:48
05/07/19
07:48

Aeglea BioTherapeutics reports Q1 EPS (59c), consensus (56c)

As of March 31, Aeglea had available cash, cash equivalents and marketable securities of $123.7M. Based on Aeglea's current operating plan, management believes it has sufficient capital resources to fund anticipated operations through Q1 of 2021.

  • 07

    Jun

AGLE Aeglea BioTherapeutics
$7.02

0.08 (1.15%)

03/21/19
JPMS
03/21/19
INITIATION
Target $14
JPMS
Overweight
Aeglea BioTherapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Aeglea BioTherapeutics with an Overweight rating and $14 price target. Aeglea is an emerging player in the rare disease space and its lead asset pegzilarginase "has multiple de-risking points" for lead indication arginase 1 deficiency, Rama tells investors in a research note. This is a disease with a clear unmet need for which there are no approved therapies to directly target cause and limited competition, the analyst adds.
09/04/18
09/04/18
DOWNGRADE
Target $10

Market Perform
Aeglea downgraded to Market Perform on potential development risk at Wells Fargo
As previously reported, Wells Fargo analyst Aeglea BioTherapeutics to Market Perform from Outperform on potential increased development risk following review of updated interim phase 1/2 data for pegzilarginase in Arginase 1 Deficiency. The analyst also lowered his price target on the shares to $10 from $24.
09/04/18
WELS
09/04/18
DOWNGRADE
WELS
Market Perform
Aeglea BioTherapeutics downgraded to Market Perform at Wells Fargo
06/14/18
BMOC
06/14/18
INITIATION
Target $21
BMOC
Outperform
Aeglea BioTherapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Matthew Luchini initiated Aeglea BioTherapeutics with an Outperform rating and a price target of $21. The analyst states that its lead drug, pegzilarginase, may "transform" the Arginase I Deficiency treatment, with the results from the Phase 1/2 trial for two patients showing improvement in clinically relevant endpoints. Luchini anticipates Q3 results to confirm the data, leading to the initiation of a phase 3 trial next year and a potential approval in 2021. The analyst adds that expansion into oncology and other preclinical studies for pegzilarginase offer further upside.

TODAY'S FREE FLY STORIES

AVP

Avon Products

$3.20

0.06 (1.91%)

05:45
05/22/19
05/22
05:45
05/22/19
05:45
Periodicals
Avon Products nearing sale to Brazil's Natura, WSJ reports »

Avon Products (AVP) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$169.62

1.26 (0.75%)

05:41
05/22/19
05/22
05:41
05/22/19
05:41
Hot Stocks
Amgen announces recommended public cash offer to the shareholders of Nuevolution »

Amgen announces a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

NVS

Novartis

$82.38

0.36 (0.44%)

05:38
05/22/19
05/22
05:38
05/22/19
05:38
Hot Stocks
Novartis: QVM149 phase II data shows improvements over current standard-of-care »

Novartis announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    May

HALO

Halozyme

$15.60

0.385 (2.53%)

05:25
05/22/19
05/22
05:25
05/22/19
05:25
Hot Stocks
Halozyme says argenx selected 2nd target under collaboration, license agreement »

Halozyme Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 31

    May

LM

Legg Mason

$36.89

1.21 (3.39%)

05:24
05/22/19
05/22
05:24
05/22/19
05:24
Upgrade
Legg Mason rating change  »

Legg Mason upgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

$25.38

-0.42 (-1.63%)

05:16
05/22/19
05/22
05:16
05/22/19
05:16
Recommendations
Sea Limited analyst commentary at Piper Jaffray »

Sea Limited price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$260.47

7.89 (3.12%)

05:13
05/22/19
05/22
05:13
05/22/19
05:13
Recommendations
Abiomed analyst commentary  »

Abiomed 20% selloff this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 13

    Nov

ABMD

Abiomed

$260.47

7.89 (3.12%)

05:10
05/22/19
05/22
05:10
05/22/19
05:10
Hot Stocks
Abiomed says FDA confirmed Impella RP heart pump is 'safe and effective' »

Abiomed yesterday …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 13

    Nov

ABMD

Abiomed

$260.47

7.89 (3.12%)

05:08
05/22/19
05/22
05:08
05/22/19
05:08
Hot Stocks
FDA says benefits of Impella RP system continue to outweigh risks »

The FDA told doctors in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 13

    Nov

FLIR

Flir Systems

$49.66

0.65 (1.33%)

05:02
05/22/19
05/22
05:02
05/22/19
05:02
Upgrade
Flir Systems rating change  »

Flir Systems upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 27

    Jun

TMDI

Titan Medical

$2.70

0.2 (8.00%)

04:59
05/22/19
05/22
04:59
05/22/19
04:59
Initiation
Titan Medical initiated at Piper Jaffray »

Titan Medical initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRXC

TransEnterix

$1.27

-0.03 (-2.32%)

04:57
05/22/19
05/22
04:57
05/22/19
04:57
Initiation
TransEnterix initiated at Piper Jaffray »

TransEnterix initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
05/22/19
05/22
04:55
05/22/19
04:55
General news
Breaking General news story  »

Week of 5/17 MBA Mortgage…

PFG

Principal Financial

$55.31

0.41 (0.75%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Principal Financial Group participates in a conference call with JPMorgan »

Life Insurance Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 11

    Jun

  • 26

    Jul

STML

Stemline

$15.07

0.71 (4.94%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Stemline management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    May

ARKAY

Arkema

$0.00

(0.00%)

, AVT

Avnet

$43.94

0.84 (1.95%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Lightfair International to hold a conference »

Lightfair 2019…

ARKAY

Arkema

$0.00

(0.00%)

AVT

Avnet

$43.94

0.84 (1.95%)

CREE

Cree

$58.84

1.41 (2.46%)

ETN

Eaton

$79.88

1.39 (1.77%)

IKTSY

Intertek

$0.00

(0.00%)

ITRI

Itron

$57.78

1.21 (2.14%)

ORCL

Oracle

$54.18

0.54 (1.01%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 04

    Jun

  • 10

    Jun

  • 20

    Aug

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Credit Suisse U.S. strategist team to hold an analyst/industry conference call »

The U.S. Sector…

MED

Medifast

$146.66

1.35 (0.93%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Medifast management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 12

    Jun

EXTR

Extreme Networks

$6.15

0.11 (1.82%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
JPMorgan telecom/IT hardware analyst to hold an analyst/industry conference call »

Telecom & IT Hardware…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

  • 30

    May

BANR

Banner Corp.

$53.76

-0.04 (-0.07%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Banner Corp. management to meet with Sandler ONeill »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 04

    Jun

CHD

Church & Dwight

$73.99

-0.02 (-0.03%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Church & Dwight management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

MSM

MSC Industrial

$75.80

0.57 (0.76%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
MSC Industrial management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 24

    May

  • 05

    Jun

  • 13

    Nov

KLIC

Kulicke & Soffa

$19.35

0.19 (0.99%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Kulicke & Soffa management to meet with Craig-Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

CINF

Cincinnati Financial

$99.25

1.07 (1.09%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Cincinnati Financial management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

JAZZ

Jazz Pharmaceuticals

$139.92

1.49 (1.08%)

04:55
05/22/19
05/22
04:55
05/22/19
04:55
Conference/Events
Jazz Pharmaceuticals management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 31

    May

  • 05

    Jun

  • 23

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.